How exercise works in the body of people with liver cirrhosis
Tests cycling or strength training in people with liver cirrhosis.
Key facts
- Who runs it
- The Cleveland Clinic
- Where
- Cleveland, United StatesSee the site
- Trial code
- Registry title
- Molecular Mechanism of Exercise in Cirrhosis
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 1 Jun 2023
- Expected to end
- 10 Aug 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Endurance Training 3 times per week
- Resistance Exercise
- Standard of Care
- Record updated
- 28 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with liver cirrhosis (scarring of the liver). It tests 12 weeks of endurance or resistance exercise against standard care.
- Age
- 21 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Cirrhosis confirmed by liver biopsy, clinical, blood or imaging criteria. Child's score 5-10 and MELD score less than 21.
- Earlier treatment
- No alcohol or recreational drugs for at least 6 months. No anabolic steroids, corticosteroids or blood thinners (anticoagulants). No liver transplant.
- Biomarker or test result
- An abdominal or liver CT scan within 1 year of enrollment is needed.
Main reasons for not taking part
- Drinking alcohol within 6 weeks of enrollment, or diabetes mellitus.
- Hepatic encephalopathy (confusion from liver disease) in the past 6 months, or a gut bleed in the past 4 weeks.
- Active cancer, active infection, or advanced heart or lung disease.
- Large fluid build-up in the belly, grade 2 or greater swollen food-pipe veins, or grade 2 leg swelling above the ankle.
- End stage kidney disease (eGFR < 15 ml/min/1.73m2) or dialysis, or not safe to exercise (failed stress test).
The registry criteria, word for word
Show all 23 criteriaShow less
Other criteria
- Inclusion
- Adult patients age 21-65 years of both genders
- Diagnosis of cirrhosis by either liver biopsy, clinical, biochemical or imaging criteria
- Child's score 5-10
- Model for End Stage Liver Disease (MELD) score less than 21
- Abstinence from alcohol and/or other recreational drugs for at least 6 months
- Absence of concurrent illnesses (renal, cardiac, pulmonary, cerebrovascular, malignancy) or medication (anabolic steroids, corticosteroids) intake that affect skeletal muscle mass, diabetes mellitus (avoid altered muscle protein metabolism), or use of anticoagulants
- abdominal or liver CT scan within 1 year of enrollment for stratification Exclusion
- Active alcohol consumption within 6 weeks of enrollment
- Pedal edema (grade 2) above the ankle will be excluded to avoid complications of the muscle biopsy
- Liver transplant
- Active Malignancy
- Recent GI bleed (4 weeks)
- Hepatic Encephalopathy within previous 6 months
- Grade 2 or greater active esophageal varices
- Active infection
- Large Ascites as defined by clinical imaging
- Advanced disease cardiac or pulmonary disease
- Use of medications affecting muscle protein turnover including corticosteroids or medications used to prevent clotting
- Clinical lab values that indicate potential poor clotting as determined by the PI
- Inability to obtain informed consent; judged likely to be unable to perform exercise or unlikely to complete the study in the opinion of the investigators
- End stage kidney disease as determined by glomerular filtration rate (eGFR) < 15 ml/min/1.73m2 or dialysis
- Patients who in the opinion of the PI are unsafe for exercise (failure to pass stress test)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 65 years old?
Where in United States
- Cleveland ClinicCleveland, United StatesContact: Annette BellarTaking people
About the trial
What the trial wants to find out
This study aims to investigate the effects of 12 weeks of resistance or endurance exercise on patients with cirrhosis. Cirrhotic patients are prone to muscle loss (sarcopenia) and ammonia build up due to liver dysfunction. The liver which in healthy patients is able to process ammonia through ureagenesis is unable to do so in cirrhosis and ammonia is taken up either by the brain causing confusion or the skeletal muscle causing muscle loss or sarcopenia. Primary sarcopenia occurs in older individuals and can be mitigated by exercise. Secondary sarcopenia occurs in response to disease such as cancer, chronic kidney disease, multiple sclerosis, and cirrhosis of all etiologies. Resistance exercise is an excellent stimulator for muscle protein synthesis and is widely used to build muscle mass and strength but has little benefit to cardiovascular function. Endurance exercise has shown to be safe in cirrhosis however there is no set prescription for cirrhosis as there is for other disease. Endurance exercise is known to promote improved cardiovascular health, improve fatigue, and generates less ammonia build up than resistance exercise. In patients with low muscle mass it is possible that endurance exercise alone will be enough to improve muscle mass. There have been few studies on exercise and cirrhosis, those that exist have shown benefits with endurance exercise. However there are even more limited studies on resistance exercise and few to no studies on the molecular mechanisms behind exercise in cirrhosis. Study visits are described fully in the protocol and consent form. After passing a screening visit patients will undergo a maximal exercise/fitness test (pre-baseline test) and other body composition measurements. After the screening and pre-baseline visit randomization will occur (2:2:1 endurance, resistance, or SOC) arrangements will be made to have the appropriate exercise equipment given to patients. Once the exercise equipment has arrived a baseline study visit will occur. After the baseline visit the endurance exercise group will cycle 3 days per week for 60 minutes under the supervision of the study team. The resistance exercise group will perform a whole body resistance workout 2 days per week for approximately 60 minutes under the supervision of a study team member.
Read full original descriptionShow less
Patients in all groups will have the fitness test repeated at weeks 4, 8 and 12. After the 12 weeks of exercise the baseline visits will be repeated and after 2 weeks patients will complete one final fitness test to examine the effects of de-training.
The 3 groups in the trial
- Endurance ArmTreatment being tested
Treatment: Endurance Training 3 times per week
- ResistanceTreatment being tested
Treatment: Resistance Exercise
- Standard of CareExisting treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Molecular Mechanism of Exercise in Cirrhosis
- Plain-language title
- How exercise works in the body of people with liver cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05982769, who can take part
- Record updated
- 28 September 2026